Eli Lilly and Company announced results from a post-hoc analysis which demonstrated efficacy of Emgality  (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with Botox (onabotulinumtoxinA).
Lilly also announced that the intended brand name, Emgality, has been conditionally accepted by the U.S. FDA.